The Competition Commission of India fined Goldman Sachs AIMPL Rs 40 lakh for not notifying it about a deal that included acquiring optionally convertible debentures in Biocon Biologics, providing significant rights beyond those of ordinary shareholders, which necessitated prior notification under the Competition Act.